Prostate Cancer

Pharma company announced draft decision for National coverage of Abarelix

Published in Cancer Weekly, January 18th, 2005

PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has issued a draft decision memorandum in support of a national coverage determination (NCD) for Abarelix (Plenaxis).

After several informal meetings with CMS following the approval of Plenaxis (abarelix for injectable suspension), PRAECIS filed a formal request with CMS for an NCD in order to ensure both consistent coverage nationwide for Plenaxis as a new class of hormonal therapy for the treatment of advanced symptomatic prostate cancer and compliance with its risk management program, known as the Plenaxis user safety (PLUS) program.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-01-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry